Pace-mapping is the primary technique used to localize the origin of ventricular tachycardia (VT) from the right ventricular outflow tract (RVOT). We previously divided the RVOT septum into 9 equal sites Isee figure) and developed a surface ECG algorithm for identifying the 9 paced sites based on the orientation of the QRS complex in leads I and aVL and the precordial R wave progression. Based on this algorithm and initial experience with catheter ablation of RVOT-VT, we hypothesized that most RVOT-VTs originate from a limited area in the RVOT. corresponding to the mid to anterior and superior RVOT septum just below the pulmonic valve (sites 2 & 3). To test this hypothesis, we documented fluoroscopically the site of identical pace-maps and successful radiofrequency (RF) catheter ablation of RVOT-VT in 14 consecutive patients (12 female; ages 23-66 years). All patients presented with palpitations and/or presyncope and left bundle branch blocklinferior VT with a right (n = 5) or left (n = 91 axis. Each patient had a structurally normal heart A lesion was considered successful if no tachycardia could be induced with atrial or ventricular pacing (± isopreterenol) after having been reproducibly initiated prior to lesion application. Result: In each patient. the site of best pace-map and successful ablation was site 2 or 3 (The figure represents a right anterior oblique view of the right ventricle:
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Conclusion:
In most patients with RVOT-VT, the site of successful RF catheter ablation was in the mid to anterior and most superior aspect of the RVOT septum. These findings may simplify the approach to RF catheter ablation of RVOT-VT and thus decrease fluoroscopic exposure in these patients. The maximum power deliverable by present radiofrequency (RF) ablation systems is limited by an impedance rise which occurs when the temperature at the electrode-tissue interface reaches 100'C. The limitation in power limits the depth and diameter of the lesion. The present method to avoid an impedance rise and maximize power delivery utilizes a thermistor in the ablation electrode. The power is varied to maintain a target temperature and prevent the temperature from exceeding 90-95'C (temperature control approach-TC). An alternative approach utilizes saline irrigation of the ablation electrode (active cooling) to prevent an impedance rise at high power (IR approach). The purpose of this study was to compare LV lesion size produced by the IR and TC approaches. In 15 anesthetized dogs (18-22 kg), a 7F deflectable catheter with a lumen and 5 mm tip electrode containing a thermistor and 6 Irrigation holes (located radially, 1 mm from tip) was inserted into a carotid artery and advanced to the LV under fluoroscopic guidance. RF current was applied at one site by manually controlling voltage (30-80 V) to maintain the electrode temperature at 80-90'C (TC) and at a second site using saline irrigation (60 mllmin) and constant voltage of 90V (IR). In 3 additional dogs with remote myocardial infarction (3--6 months), a total of 4 RF lesions was made at the border of the scar, all by IR approach (fR M I). The 15 dogs were sacrificed 6 days after ablation and the 3 dogs with infarction were sacrificed 4 hours after ablation. Conclusions: 1) Electrode cooling by saline irrigation allows sustained RF energy at high power; producing larger and deeper lesions in normal LV myocardium; 2) the deeper lesions with a cooler electrode suggests direct resistive heating occurs relatively far from the electrode; and 3) reasonable lesions can be obtained in infarcted LV using irrigation.
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Results:
:45
Post-Infarct Ventricular Tachycardia Of the 17 pts with complete success, 10 received no other treatment. 5 had an implantable defibrillator and 2 pts remained on prior antiarrhythmic drugs. No clinical recurrences or implantable defibrillator discharges occurred in any of these pts after a mean follow-up of 6 ± 4 months. Follow-up stimulation 3 months later showed no inducible VT in 8/10 pts 180%) discharged without inducible VT. Of the 5 pts with partial success, 3 have had a marked decrease in frequency of VT recurrences. None of the documented recurrences was fatal. One pt with frequent episodes of stable VT for years had possible sudden death 2 months post CA (without symptoms in interim).
The mean cycle length of successfully ablated VTs was 366 ± 74 ms vs 312 ± 51 ms for unsuccessfully ablated VTs (p < 0.01).
Conclusions: 1) Immediate and long term success can be achieved with aggressive radiofrequency CA in a majority of patients with sustained monomorphic VT post-infarct. even when multiple VT morphologies are present. 2) VTs with cycle length <400 ms can be successfully ablated but faster VTs are less easily ablated, not entirely related to hemodynamic tolerance. Infarct size reduction after ischemic preconditioning has been reported as an all-or-nothing response, with a threshold of 2 to 5 min of preconditioning ischemia time. Furthermore, infarct size reduction is associated with glycogen depletion before prolonged ischemia. We sought to determine whether increasing preconditioning ischemia time results in progressive myocardial glycogen depletion and infarct size reduction and if so, whether I~farct size reduction correlates with glycogen depletion before prolonged Ischemia. Therefore, ventilated rats underwent a single episode of preconditioning is-chemia lasting 1.25 (n~18), 2.5 (n = 20), 5 (n = 9), or 10 (n~161 min, or multiple episodes cumulating in 10 (2 x 5 min, n = 17) or 20 (4 x 5 min, n = 13 or 2 x 10 min, n = 14) min of preconditioning ischemia time, all followed by 5 min of reperfusion. Control rats (n~22) were not preconditioned. In separate groups, glycogen was determined before whereas infarct size was determined after prolonged ischemia (45 min) and reperfusion (120 min). Myocardial glycogen levels and infarct size are shown as a function of preconditioning ischemia time.
Preconditioning and Stunning
Protocol I, dogs received 45-min episodes of preconditioning ischemia (PC: n = 7) or a comparable control period In~9) before sustained CO; Protocol II was identical except polymyxin-B (PMX: 50 mg/kg) was administered throughout the PC regimen (n = 6) or control period (n = 6). Blood flow to the ischemic subendocardium was assessed during sustained CO by injection of ratJiolabeled microspheres, and area of necrosis (AN) was delineated by tetrazolium staining and expressed as a % of the area at risk of infarction (ARI. Preconditioning (PC) prevents ventricular fibrillation (VF) in the rat heart. We sought to determine whether this protective effect might: (11 apply to the pig heart, (2) be related to modifications of electrophysiologic parameters. Fortyeight anesthetized pigs underwent 40 min of LAD coronary artery occlusion (CO) followed by 2 hours of reperfusion (R) Prior to this, PC hearts received 10 min of CO and 10 min of R. Area at risk and infarct size were measured by injection of blue dye and triphenyltetrazolium staining, respectively. Duration of subepicardial monophasic action potential (MAPD) and VF threshold were measured at different time points of the experiment. As expected, infarct size was significantly reduced in PC hearts, averaging 6 ± 4%' of the risk region versus 28 ± 4% in controls (* p < 0.01). But, incidence of VF was not reduced in the PC group: 69% vs 63% in the control group (p = NSI. Furthermore, time to VF during the 40 minute CO was significantly shorter in PC than in control hearts: 7 ± 2 min' vs 18 ± 2 min 1* p < 0.01). This was associated with a significantly lower VF threshold and shortening of MAPD in PC hearts at the onset of the sustained CO. At 3 min of ischemia, VF threshold averaged 2.3 ± 1.7 mAIO in PC vs 4.1 ± 2.4 mA in controls (* p < 0.01 vs control). MAPD averaged 197 ± 4 ms' in PC hearts versus 214 ± 4 ms in controls 1* p < 0.05). This suggests that preconditioning does not prevent but accelerates ventricular fibrillation in pig hearts via a decrease of the fibrillation threshold and a shortening of monophasic action potential during the first minutes of the sustained ischemia.
Protocol I confirmed the expected reduction in infarct size in preconditioned dogs vs. controls. Protocol II revealed that all PM X-treated dogs were rendered profoundly ischemic during CO. Nonetheless, treatment with PMX did not attenuate the reduction in infarct size achieved with preconditioning. Thus, the PKC inhibitor polymyxin-B may exacerbate ischemia during CO: this may contribute to the previously reported "increase" in infarct size in preconditioned rabbits treated with this agent. Polymyxin-B did not, however, block the cardioprotective effects of preconditioning in this canine model. In addition, infarct size reduction correlated with glycogen depletion before prolonged ischemia (r = 0.98; 19 P < 0.001). Thus, increasing preconditioning ischemia time results in progressive myocardial glycogen depletion and infarct size reduction, reaching a maximal effect when the preconditioning ischemia time is :0:5 min. This maximal effect may be due to marked depletion of myocardial glycogen stores before prolonged ischemia. The anti-infarct effect of ischemic preconditioning (PC) is partly due to adenosine receptor-mediated opening of KATP channels. PC-mediated protection may be potentiated by exogenous infusion of adenosine receptor agonists. To test this hypothesis, pentobarbital anesthetized rabbits (n = 8/group) underwent two cycles of 5 min regional ischemia and 5 min coronary reperfusion (REP; i.e., PC) followed by 30 min ischemia and 3 h REP Rabbits received either adenosine (AD; 0.01 mg/min); cyclopentyladenosine (CP; Al receptor agonist; 0.001 mg/minl or CGS 21680 (CG; A2 receptor agonist; 001 mg/min), i. v. for 65 min starting 5 min before onset of REP K ATP channels were blocked with i.v. glibenclamide (G; 0.15 mglkg) 10 min before PC in the absence or presence of AD, CP or CG. Infarct and risk (R; cm 3 ) volume was assessed with tetrazolium and microsphere autoradiography. Infarct size (IS) was normalized to R. IS in absolute controls (i.e., no PC) was 51 ± 6% (mean ±SEMI R Cardiodynamics were similar for the treatment groups; but heart rateblood pressure product was lower (p ::: 0.05) during CP infusion. Conclusions: 1) PC markedly reduced IS; 2) PC-mediated protection was not potentiated with exogenous AD, CP or CG; and 3) G abolished PC-mediated protection withouVwith exogenous AD, CP or CG. These data indicate that adenosine receptor activation and opening of KATP channels are involved in Pc.
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The In the rabbit model, administration of protein kinase C IPKCI inhibitors such as polymyxin-B have been reported to attenuate the reduction in infarct size achieved with ischemic preconditioning. Activation of PKC has therefore been proposed to playa crucial role in the mechanism by which preconditioning protects the heart from subsequent sustained coronary occlusion (CO). However, the possible confounding effects of PKC inhibition on myocardial blood flow were not assessed in these studies. We addressed this issue in 28 dogs subjected to 1 h of sustained CO and 4-5 h of reperfusion. In Calcitonin gene-related peptide (CGRP) has been found to have inotropic properties and a short half-life. CGRP has been demonstrated to reduce ischemic injury in tissue flaps as well as to increase coronary artery flow, while other available inotropes have been shown to impair recovery from myocardial ischemia. Yet, a therapeutic role for CGRP in myocardial ischemia has not been defined. Therefore, CGRP was compared to placebo in nine chronically instrumented conscious dogs who underwent two 15 minute left anterior descending coronary artery occlusions separated by at least 24 hours of reperfusion. Left ventricular transmural pressure and myocardial segment length were measured at control and during reperfusion. Either CGRP (0.07 Ilg/kglmin) or saline placebo was randomly chosen and continuously infused from 45 to 105 minutes of reperfusion. The alternative infusion was given during the second study. Regional function was assessed using preload recruitable work area (PRWA), a load-insensitive measure of regional myocardial performance. PRWA was calculated as the area beneath the linear stroke work vs. end-diastolic length relationship. Data are mean PRWA (% of con-
